Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06053164 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 9, 2026 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. 10 versions Re-verified since Jul 21, 2025, no change to tracked fieldsv16-v25
  2. Start date: May 21, 2025 to Jul 1, 2025v15
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: May 1, 2025 to May 21, 2025
    v14
  4. Start date: Apr 1, 2025 to May 1, 2025v13
  5. Start date: Mar 1, 2025 to Apr 1, 2025v12
Show 10 earlier versionsHide 10 earlier versions
  1. Start date: Feb 1, 2025 to Mar 1, 2025v11
  2. Re-verified, no change to tracked fieldsv10
  3. Primary and study completion dates: Sep 1, 2025 to Sep 1, 2026
    • Start date: Oct 1, 2024 to Feb 1, 2025
    v9
  4. Re-verified, no change to tracked fieldsv8
  5. Start date: Jun 28, 2024 to Oct 1, 2024v7
  6. Re-verified, no change to tracked fieldsv6
  7. Start date: Feb 28, 2024 to Jun 28, 2024v5
  8. Start date: Jan 31, 2024 to Feb 28, 2024v4
  9. Start date: Oct 31, 2023 to Jan 31, 2024v3
  10. Secondary endpoints: details revised at 6 of 6 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators plan to conduct a study to find out if giving portable oxygen therapy (during physical activity) to patients with interstitial lung disease will improve quality of life, exercise tolerance, shortness of breath, and blood vessel function. Oxygen will be provided for a period of 8 weeks. Additionally, the investigators plan to investigate if it is helpful to deliver individualized support when providing oxygen therapy, through check-in phone calls with a respiratory therapist and by providing additional educational material.
Trial Details
NCT Number NCT06053164
Lead Sponsor University of Alberta
Collaborators: Alberta Boehringer Ingelheim Collaboration
Conditions
(from sponsor)		 Fibrotic Interstitial Lung Disease
Related terms Lung Diseases, Interstitial
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov